Thus, we decided to model MLL3 mutation with lentiviral shRNA knockdown (KD) in the ER+ breast cancer cell line ZR751 in order to maintain some residual expression of wildtype MLL3 (Figure S2A). The gene discussed is KMT2C; the disease is breast carcinoma.